Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message

Executive Summary

Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.

Related Content

Gottlieb Wants His US FDA Team To Stay Together After He Departs
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
US FDA Targets Migraine, Schizophrenia And Opioid Sparing Drugs For Clinical Outcome Assessment Development
Commissioner Succession Plan? Abernethy As Gottlieb’s Number Two Offers One Option
Gottlieb Takes Aim At CROs’ ‘Outdated Processes’ In Push For Clinical Trial Digitization
Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock
Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock
Gottlieb's Confirmation: Will Industry Ties Remain A Big Deal After The Hearing?
NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’
FDA’s Clinical Trial Inclusion Policy Sold As Mild And Gentle





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts